Mandai M, Konishi I, Koshiyama M, Komatsu T, Yamamoto S, Nanbu K, Mori T, Fukumoto M
Department of Gynecology and Obstetrics, Faculty of Medicine, Kyoto University, Japan.
Cancer. 1995 May 15;75(10):2523-9. doi: 10.1002/1097-0142(19950515)75:10<2523::aid-cncr2820751019>3.0.co;2-l.
The reduced expression of nm23-H1 protein and/or overexpression of c-erbB-2 protein reportedly is associated with a high incidence of lymphatic metastasis or poor prognosis of the patient in a variety of human malignant tumors.
The expression patterns of nm23-H1 and c-erbB-2 proteins were analyzed by immunohistochemical staining using formalin fixed, paraffin embedded sections of 88 cases of invasive carcinoma (39 matched pairs of adenocarcinoma and squamous cell carcinoma, 8 cases of adenosquamous carcinoma, and 2 cases of undifferentiated carcinoma) and 31 cases of preinvasive lesions of the uterine cervix.
Expression of nm23-H1 was detected in 46% of adenocarcinoma and in 36% of squamous cell carcinoma of the uterine cervix, whereas c-erbB-2 expression was evident in 49% and 38%, respectively. Negative expression of nm23-H1, positive expression of c-erbB-2, and a combined nm23-H1-negative and c-erbB-2-positive expression were associated with a high incidence of lymph node involvement (P = 0.36, P = 0.0015, P = 0.0055, respectively) and with poor prognosis of patients (P = 0.034, P = 0.014, P = 0.00008, respectively) with adenocarcinoma of the uterine cervix, but not in those with squamous cell carcinoma. Multivariate analysis using the Cox's proportional hazard model also revealed that these three factors significantly contributed to the prognosis of patients with cervical adenocarcinoma.
Reduced expression of the nm23-H1 protein, increased expression of the c-erbB-2 protein, and a combined nm23-H1-negative and c-erbB-2-positive expression have prognostic significance in patients with adenocarcinoma, whereas they may not be associated with the prognosis of squamous cell carcinoma of the uterine cervix, nm23-H1 and c-erbB-2 proteins may have different functions according to the subtype of cervical carcinoma.
据报道，nm23-H1蛋白表达降低和/或c-erbB-2蛋白过表达与多种人类恶性肿瘤患者的高淋巴转移发生率或不良预后相关。
采用免疫组织化学染色法，对88例浸润性癌（39对配对的腺癌和鳞状细胞癌、8例腺鳞癌和2例未分化癌）及31例子宫颈浸润前病变的福尔马林固定、石蜡包埋切片进行nm23-H1和c-erbB-2蛋白表达模式分析。
子宫颈腺癌中46%检测到nm23-H1表达，鳞状细胞癌中36%检测到nm23-H1表达；而c-erbB-2表达在腺癌和鳞状细胞癌中分别为49%和38%。nm23-H1阴性表达、c-erbB-2阳性表达以及nm23-H1阴性和c-erbB-2阳性联合表达与子宫颈腺癌患者的高淋巴结转移率（分别为P = 0.36、P = 0.0015、P = 0.0055）及不良预后（分别为P = 0.034、P = 0.014、P = 0.00008）相关，但在鳞状细胞癌患者中无此相关性。使用Cox比例风险模型进行多因素分析还显示，这三个因素对子宫颈腺癌患者的预后有显著影响。
nm23-H1蛋白表达降低、c-erbB-2蛋白表达增加以及nm23-H1阴性和c-erbB-2阳性联合表达对腺癌患者具有预后意义，而它们可能与子宫颈鳞状细胞癌的预后无关，nm23-H1和c-erbB-2蛋白可能根据子宫颈癌的亚型具有不同功能。
